AI-generated analysis. Always verify with the original filing.
Optimi Health Corp. is a Canadian GMP-compliant pharmaceutical drug manufacturer licensed by Health Canada for handling controlled substances, specializing in MDMA and botanical psilocybin products from two 10,000-square-foot facilities in Princeton, British Columbia. Operating under a Drug Establishment Licence (DEL) and Dealer’s Licence (DL), the company supplies prescription MDMA for PTSD and psilocybin for treatment-resistant depression (TRD) in Australia via the Authorised Prescribers Scheme, and supports clinical trials in Canada and Israel. Financially, it reported revenue of C$426,301 for FY2025 (up from C$389,850 in FY2024) but incurred a net loss of C$3.7 million with accumulated deficit of C$27.2 million and cash of C$1.1 million as of September 30, 2025. The company is pursuing a Nasdaq uplisting under 'OPTH' via this F-1/A filing dated February 17, 2026, with a planned reverse share split to meet minimum price requirements. Net proceeds, estimated at US$ million from the midpoint price, will fund production scaling in current markets, market expansion to Israel and the US, sales growth, and working capital. As an emerging growth company and foreign private issuer, Optimi leverages regulatory approvals and vertical integration for competitive advantages in the nascent psychedelic therapeutics sector, positioning for growth amid evolving global regulations.
Offering Amount
$20.7M
Shares Offered
96,776,919
Issuer Type
Share Type
Common shares
Exchange
Nasdaq Capital Market
Ticker
OPTH
Use of Proceeds: Scaling production and distribution in current markets, additional market expansion to Israel and United States, sales growth, general working capital and other operating expenses.
Canadian GMP compliant pharmaceutical drug manufacturer licensed by Health Canada for handling controlled substances, specializing in MDMA and psilocybin derived from botanical sources with vertically integrated 20,000 sq ft facilities.